Business Wire

Syncron Accelerates Growth by Joining the AWS ISV Accelerate Program

23.1.2025 14:00:00 CET | Business Wire | Press release

Share

Syncron, a leading provider of intelligent Service Lifecycle Management solutions, announced today that it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program. This co-sell program supports AWS Partners that offer software solutions running on or integrating with AWS, connecting them with the AWS Sales organization to drive new business and accelerate sales cycles.

Unlocking New Growth Opportunities with AWS

By joining the AWS ISV Accelerate Program, Syncron gains focused co-selling support from AWS, as well as access to sales enablement resources, including educational events and solution libraries. Through this partnership, Syncron will collaborate closely with AWS Sales teams, providing better customer outcomes through its integrated and optimized cloud solutions for after-sales services.

Joining the program also enhances Syncron's visibility within the AWS ecosystem, ensuring that AWS Account Managers can actively support the promotion and sale of Syncron’s solutions, benefiting both current and prospective customers.

Claire Rychlewski, Chief Revenue Officer at Syncron, commented on Syncron’s strengthened relationship with AWS: “Being part of the AWS ISV Accelerate Program is a game-changer for Syncron. This collaboration means our solutions are now fully aligned with the AWS commitment to supporting software providers in driving innovative customer-focused outcomes. The opportunity to co-sell with AWS opens new avenues for growth and makes it easier for our customers to access our solutions directly through the AWS Marketplace.”

Through the AWS Marketplace, Syncron customers will gain numerous benefits, including a streamlined procurement process, improved licensing flexibility, and procurement efficiencies that translate into time and cost savings. Customers will also be able to leverage their existing AWS budget allocations to purchase Syncron's AI-powered service lifecycle management solutions, making it easier for organizations already working with AWS to benefit from Syncron's software offerings. Syncron's AI-powered Service Lifecycle Management (SLM) solutions help OEMs and distributors in the automotive, construction, mining, agricultural and industrial equipment, medical devices, consumer durables, high tech, aerospace and other industries successfully transition to future service-driven business models by optimizing service quality and delivery to increase customer loyalty. With more than $3 billion in annual value creation, Syncron connects and synchronizes every aspect of aftermarket service.

In just under eight months, Syncron has progressed from listing its Software as a Service (SaaS) products on AWS Marketplace to joining the ISV Accelerate Program – a notable achievement that highlights Syncron's commitment to advancing strategic partnerships and delivering value to customers worldwide.

About Syncron

Syncron helps manufacturers and distributors capitalize on the new service economy by increasing customer loyalty and optimizing aftermarket profitability. Syncron's integrated, scalable, state-of-the-art Service Lifecycle Management (SLM) cloud platform puts data at the heart of aftermarket operations to unlock service synergies, significant revenue opportunities and help companies differentiate themselves with exceptional aftermarket customer experiences. The world’s top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more, visit syncron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250123527061/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye